Literature DB >> 25133040

Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide.

Arun Swaminath1, Raja Taunk1, Garrett Lawlor1.   

Abstract

Methotrexate has been used an immunomodulator in many autoimmune diseases, including inflammatory bowel disease. However, many physicians are unfamiliar or uncomfortable with its use in the management of inflammatory bowel disease. We summarize the data for use of methotrexate in common clinical scenarios: (1) steroid dependant Crohn's disease (CD); (2) maintenance of remission in steroid free CD; (3) azathioprine failures in CD; (4) in combination therapy with Anti-TNF agents in CD; (5) decreasing antibody formation to Anti-TNF therapy in CD; (6) management of fistulizing disease in CD; and (7) as well as induction and maintenance of remission in ulcerative colitis. An easy to use algorithm is provided for the busy clinician to access and safely prescribe methotrexate for their inflammatory bowel disease patients.

Entities:  

Keywords:  Crohn’s disease; Immunomodulators; Inflammatory bowel disease; Methotrexate; Methotrexate user’s guide; Ulcerative colitis

Year:  2014        PMID: 25133040      PMCID: PMC4133437          DOI: 10.4292/wjgpt.v5.i3.113

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  35 in total

1.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

Authors:  B G Feagan; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W McDonald
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

2.  Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-experts.

Authors:  Arun Swaminath; Benjamin Lebwohl; Kristina M Capiak; Daniel H Present
Journal:  Dig Dis Sci       Date:  2010-12-23       Impact factor: 3.199

3.  Methotrexate in systemic lupus erythematosus.

Authors:  J Wenzel
Journal:  Lupus       Date:  2005       Impact factor: 2.911

4.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Authors:  Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts
Journal:  Gut       Date:  2007-01-17       Impact factor: 23.059

Review 5.  When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.

Authors:  Suneeta Krishnareddy; Arun Swaminath
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

6.  6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease.

Authors:  J Maté-Jiménez; C Hermida; J Cantero-Perona; R Moreno-Otero
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-11       Impact factor: 2.566

7.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

8.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

Authors:  R A Kozarek; D J Patterson; M D Gelfand; V A Botoman; T J Ball; K R Wilske
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

9.  Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease.

Authors:  A Wilson; V Patel; N Chande; T Ponich; B Urquhart; L Asher; Y Choi; R Tirona; R B Kim; J C Gregor
Journal:  Aliment Pharmacol Ther       Date:  2012-11-28       Impact factor: 8.171

10.  Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.

Authors:  O Schröder; I Blumenstein; A Schulte-Bockholt; J Stein
Journal:  Aliment Pharmacol Ther       Date:  2004-02-01       Impact factor: 8.171

View more
  6 in total

1.  The Current Role of Methotrexate in Patients With Inflammatory Bowel Disease.

Authors:  Joel R Rosh
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-01

Review 2.  Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.

Authors:  Gerda C Leitner; Harald Vogelsang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 3.  Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era.

Authors:  Gerassimos J Mantzaris
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

Review 4.  The impact of inflammatory bowel disease on oral health.

Authors:  J S Chandan; T Thomas
Journal:  Br Dent J       Date:  2017-04-07       Impact factor: 1.626

Review 5.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

Review 6.  Pharmacologic therapy for inflammatory bowel disease refractory to steroids.

Authors:  M P Martínez-Montiel; B Casis-Herce; G J Gómez-Gómez; A Masedo-González; C Yela-San Bernardino; C Piedracoba; G Castellano-Tortajada
Journal:  Clin Exp Gastroenterol       Date:  2015-08-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.